SCHEMBL4376197

SCHEMBL4376197

COS(=O)(=O)CCC(=O)O

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
APEX1 P27695 2/20 0.52
HTT P42858 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
TSHR P16473 3/20 0.39
LMNA P02545 4/20 0.38
EGLN1 Q9GZT9 2/20 0.38
ALKBH5 Q6P6C2 1/20 0.38
SUCNR1 Q9BXA5 1/20 0.38
ALDH1A1 P00352 2/20 0.38
FFAR3 O14843 1/20 0.38
HDAC3 O15379 1/20 0.38
HDAC1 Q13547 1/20 0.38
HDAC2 Q92769 1/20 0.38
HDAC8 Q9BY41 1/20 0.38
KMT2A Q03164 1/20 0.37
SLC15A2 Q16348 1/20 0.36
KDM4E B2RXH2 1/20 0.35
SLC22A6 Q4U2R8 1/20 0.35
NFKB1 P19838 1/20 0.33
PMP22 Q01453 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL577101 0.79 APEX1 (0.57) APEX1HTTNPSR1TSHRLMNA
SCHEMBL28227352 0.78 CA1 (0.33) TSHRKDM4ECA12CA14
SCHEMBL4373861 0.78 TSHR (0.55) HTTTSHRLMNAALDH1A1KMT2A
SCHEMBL28217965 0.76 CA1 (0.32) CA12CA14
SCHEMBL13715454 0.76 APEX1 (0.48) APEX1HTTNPSR1TSHRLMNA
SCHEMBL15257418 0.75 APEX1 (0.46) APEX1HTTNPSR1TSHRLMNA
SCHEMBL778652 0.74 USP2 (0.44) TSHR
SCHEMBL10306587 0.74
SCHEMBL28018015 0.71 ALDH1A1 (0.39) HTTTSHRLMNAALDH1A1KMT2A
SCHEMBL28121803 0.71 APEX1 (0.48) APEX1HTTNPSR1TSHRLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-103284974-B Benzene ring nonyl ester double-layer osmotic pump controlled-release tablet and preparation method thereof WUHAN GENERAL HOSPITAL OF GUANGZHOU MILITARY COMMAND, PLA (CN) 2016-01-20 CN claimed
CN-103860514-A Oxybutynin hydrochloride osmotic pump controlled release tablets and preparation method thereof HEFEI HUAFANG PHARMACEUTICAL SCIENCES & TECHNOLOGY CO LTD 2014-06-18 CN claimed
CN-103284974-A Phencynonate hydrochloride double-layer osmotic pump controlled release tablet and preparation method thereof WUHAN GENERAL HOSPITAL OF GUANGZHOU MILITARY 2013-09-11 CN claimed
CN-102552205-A Potassium citrate controlled-release tablet preparation and preparation method thereof SHANGHAI INST MATERIA MEDICA 2012-07-11 CN claimed
CN-102488671-A Lamivudine controlled release tablet preparation and preparation method thereof HEFEI HUAFANG PHARMACEUTICAL SCIENCES & TECHNOLOGY CO LTD 2012-06-13 CN claimed
CN-102144985-A Potassium chloride elementary osmotic pump controlled release tablet and preparation method thereof SHANGHAI INST MATERIA MEDICA 2011-08-10 CN claimed
EP-1592733-B1 MICROSPHERES AKZO NOBEL NV (NL) 2009-07-08 EP claimed
CN-100354346-C Microspheres AKZO NOBEL NV (NL) 2007-12-12 CN claimed
CN-1805734-A Biphasic release of glipizide from monocompartment osmotic dosage form RANBAXY LAB LTD (IN) 2006-07-19 CN claimed
CN-1738853-A Microspheres AKZO NOBEL NV (NL) 2006-02-22 CN claimed
EP-1592733-A1 MICROSPHERES Akzo Nobel N.V. (NL) 2005-11-09 EP claimed
US-20040249005-A1 eliminating residual monomers such as (meth)acrylonitrile from thermoplastic expandable microspheres of a thermoplastic polymer shell encapsulating a propellant, by contacting with oxo acids of sulfur such as a bisulfite to form 2-cyano-ethanesulfonic acid for example AKZO NOBEL N.V. (NL) 2004-12-09 US claimed
WO-2004072160-A1 MICROSPHERES AKZO NOBEL N.V. (NL) 2004-08-26 WO claimed
US-20230265121-A9 CONJUGATED NEUROACTIVE STEROID COMPOSITIONS AND METHODS OF USE DUKE UNIVERSITY 2023-08-24 US disclosed
CN-103860514-B A kind of ditropan XL osmotic pump controlled release tablet and preparation method thereof 合肥华方医药科技有限公司 2016-06-08 CN disclosed
CN-103284974-B Benzene ring nonyl ester double-layer osmotic pump controlled-release tablet and preparation method thereof WUHAN GENERAL HOSPITAL OF GUANGZHOU MILITARY COMMAND, PLA (CN) 2016-01-20 CN disclosed
CN-1125573-A The use of asymmmetric membranes in delivery devices PFIZER (US) 1996-07-03 CN disclosed
EP-0702697-A1 METHOD OF MAKING AMIDE MODIFIED CARBOXYL-CONTAINING POLYSACCHARIDE AND FATTY AMIDE-MODIFIED POLYSACCHARIDE SO OBTAINABLE Akzo Nobel N.V. (NL) 1996-03-27 EP disclosed
WO-1994024169-A1 METHOD OF MAKING AMIDE MODIFIED CARBOXYL-CONTAINING POLYSACCHARIDE AND FATTY AMIDE-MODIFIED POLYSACCHARIDE SO OBTAINABLE AKZO NOBEL N.V. (NL) 1994-10-27 WO disclosed
CN-1042072-A Asymmetric membranes for use in delivery assemblies PFIZER (US) 1990-05-16 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230265121-A9 CONJUGATED NEUROACTIVE STEROID COMPOSITIONS AND METHODS OF USE SHBG, TACR2, GAP43 APEX1 2942/4885HTT 2692/4885NPSR1 12/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.